NCT05929066
TRIUMPH — retatrutide obesity program
Phase Phase 3
Status Recruiting
Indication Obesity
Enrollment 2,100
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT05929066
- Phase
- Phase 3
- Status
- Recruiting
- Indication
- Obesity
- Primary completion
- 11/1/2026
- Enrollment (planned/actual)
- 2,100
- Sponsor
- Eli Lilly
- Peptide
- Retatrutide
Peptide under study
Retatrutide
GIP / GLP-1 / glucagon triple agonist · Phase 3